Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
PENG Bin
PENG Bin
Positions:

Global Head of TCO Shanghai

Company:

Novartis

Bin Peng received his MD degree from Sun Yet-sen University of Medical Sciences in Guangzhou, China. He then earned PhD of Cancer Clinical Pharmacology at Cancer Research Unit, University of Newcastle upon Tyne, UK  and completed postdoc- fellowship in Pharmaceutical School, Manchester University, UK . Then he joined Novartis Pharma AG, Basel, Switzerland as senior clinical pharmacologist. He has been involved in Gleevec (STI571, the first target chemotherapy drug for cancer treatment) entire clinical development from 1998 with the phase I study in man to the registration worldwide in 2001.  He joined CPDM/Oncology, GSK, USA as Director of Clinical Pharmacology in 2005. His research interests have focused on the Phase I, Cancer Translational Medicine, human PK/PD and early clinical development of anticancer and hematology drugs. He has authored more than 70 papers and abstracts on clinical pharmacology and early clinical investigation in the field of anticancer/hematology drugs. He re-joined oncology translational medicine (OTM) department, Novartis as global head of TCO Shanghai in 2009.